Thomas F. Rogers

Thomas F. Rogers

Auto-generated profile, based on publicly available information

Thomas F. Rogers

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Science
Verified
Journal Article
Open access
PDF file
TRThomas F. Rogers
Thomas F. Rogers
FZFangzhu Zhao
Fangzhu Zhao
DHDeli Huang
Deli Huang
NBNathan Beutler
Nathan Beutler
ABAlison Burns
Alison Burns
DBDennis R. Burton
Dennis R. Burton
Protective neutralizing antibodies: Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Rogers et al. used a high-throughput pipeline to isolate and characterize monoclonal antibodies from convalescent donors. Antibodies were selected for binding to the viral spike protein, which facilitates entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. Most isolated antibodies bound to regions of the spike outside of the receptor binding domain (RBD); however, a larger proportion of the RBD-binding antibodies were neutralizing, with the most potent binding at a site that overlaps the ACE2 binding site. Two of the neutralizing antibodies were tested in Syrian hamsters and provided protection against SARS-CoV-2 infection. Science , this issue p. 956

28 August 2020 in Science
Verified
Journal Article
Open access
PDF file
MYMeng Yuan
Meng Yuan
Hejun LiuHejun Liu
Hejun Liu
Nicholas WuNicholas Wu
Nicholas Wu
CLChang-Chun D. Lee
Chang-Chun D. Lee
XZXueyong Zhu
Xueyong Zhu
IWIan A. Wilson
Ian A. Wilson
A common theme in antibody responses: In the fight against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), antibodies are a key tool, both as potential therapeutics and to guide vaccine development. Yuan et al. focused on finding shared antibody responses, in which multiple individuals develop antibodies against the same antigen using the same genetic elements and modes of recognition. The authors identified the immunoglobulin heavy-chain variable region 3-53 gene as the most frequently used among 294 antibodies that target the receptor-binding domain (RBD) of the viral spike protein. These antibodies have few somatic mutations, and crystal structures of two neutralizing antibodies bound to the RBD show that mostly germline-encoded residues are involved in binding. The minimal affinity maturation and high potency of these antibodies is promising for vaccine design. Science , this issue p. 1119

18 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BBBritton Boras
Britton Boras
RJRhys M. Jones
Rhys M. Jones
BABrandon J. Anson
Brandon J. Anson
DADan Arenson
Dan Arenson
LALisa Aschenbrenner
Lisa Aschenbrenner
CACharlotte Allerton
Charlotte Allerton
COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease is a virally encoded protein that is essential across a broad spectrum of coronaviruses with no close human analogs. PF-00835231, a 3CL protease inhibitor, has exhibited potent in vitro antiviral activity against SARS-CoV-2 as a single agent. Here we report, the design and characterization of a phosphate prodrug PF-07304814 to enable the delivery and projected sustained systemic exposure in human of PF-00835231 to inhibit coronavirus family 3CL protease activity with selectivity over human host protease targets. Furthermore, we show that PF-00835231 has additive/synergistic activity in combination with remdesivir. We present the ADME, safety, in vitro, and in vivo antiviral activity data that supports the clinical evaluation of PF-07304814 as a potential COVID-19 treatment.

23 March 2022 in Science Translational Medicine
Verified
Journal Article
Open access
PZPanpan Zhou
Panpan Zhou
MYMeng Yuan
Meng Yuan
GSGe Song
Ge Song
NBNathan Beutler
Nathan Beutler
NSNamir Shaabani
Namir Shaabani
RARaiees Andrabi
Raiees Andrabi
Broadly neutralizing antibodies (bnAbs) to coronaviruses (CoVs) are valuable in their own right as prophylactic and therapeutic reagents to treat diverse CoVs and as templates for rational pan-CoV vaccine design. We recently described a bnAb, CC40.8, from a CoV disease 2019 (COVID-19) convalescent donor that exhibits broad reactivity with human β-CoVs. Here, we showed that CC40.8 targets the conserved S2 stem helix region of the CoV spike fusion machinery. We determined a crystal structure of CC40.8 Fab with a SARS-CoV-2 S2 stem peptide at 1.6-Å resolution and found that the peptide adopted a mainly helical structure. Conserved residues in β-CoVs interacted with CC40.8 antibody, thereby providing a molecular basis for its broad reactivity. CC40.8 exhibited in vivo protective efficacy against SARS-CoV-2 challenge in two animal models. In both models, CC40.8-treated animals exhibited less weight loss and reduced lung viral titers compared to controls. Furthermore, we noted that CC40.8-like bnAbs are relatively rare in human COVID-19 infection, and therefore, their elicitation may require rational structure-based vaccine design strategies. Overall, our study describes a target on β-CoV spike proteins for protective antibodies that may facilitate the development of pan–β-CoV vaccines.

20 October 2021 in Science Translational Medicine
Verified
Journal Article
Open access
HCHyeseon Cho
Hyeseon Cho
KGKristina Kay Gonzales-Wartz
Kristina Kay Gonzales-Wartz
DHDeli Huang
Deli Huang
MYMeng Yuan
Meng Yuan
MPMary Peterson
Mary Peterson
JTJoshua Tan
Joshua Tan
Bispecific antibodies targeting multiple regions of the SARS-CoV-2 spike protein comparably neutralize variants of concern and wild-type virus.

3 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMalina Bakowski
Malina Bakowski
NBNathan Beutler
Nathan Beutler
KWKaren C. Wolff
Karen C. Wolff
MKMelanie G. Kirkpatrick
Melanie G. Kirkpatrick
ECEmily Chen
Emily Chen
TRThomas F. Rogers
Thomas F. Rogers
The ongoing pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), necessitates strategies to identify prophylactic and therapeutic drug candidates for rapid clinical deployment. Here, we describe a screening pipeline for the discovery of efficacious SARS-CoV-2 inhibitors. We screen a best-in-class drug repurposing library, ReFRAME, against two high-throughput, high-content imaging infection assays: one using HeLa cells expressing SARS-CoV-2 receptor ACE2 and the other using lung epithelial Calu-3 cells. From nearly 12,000 compounds, we identify 49 (in HeLa-ACE2) and 41 (in Calu-3) compounds capable of selectively inhibiting SARS-CoV-2 replication. Notably, most screen hits are cell-line specific, likely due to different virus entry mechanisms or host cell-specific sensitivities to modulators. Among these promising hits, the antivirals nelfinavir and the parent of prodrug MK-4482 possess desirable in vitro activity, pharmacokinetic and human safety profiles, and both reduce SARS-CoV-2 replication in an orthogonal human differentiated primary cell model. Furthermore, MK-4482 effectively blocks SARS-CoV-2 infection in a hamster model. Overall, we identify direct-acting antivirals as the most promising compounds for drug repurposing, additional compounds that may have value in combination therapies, and tool compounds for identification of viral host cell targets.